JP2010522137A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522137A5
JP2010522137A5 JP2009540891A JP2009540891A JP2010522137A5 JP 2010522137 A5 JP2010522137 A5 JP 2010522137A5 JP 2009540891 A JP2009540891 A JP 2009540891A JP 2009540891 A JP2009540891 A JP 2009540891A JP 2010522137 A5 JP2010522137 A5 JP 2010522137A5
Authority
JP
Japan
Prior art keywords
composition
effective amount
risperidone
day
hydroxyrisperidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009540891A
Other languages
English (en)
Other versions
JP4643742B2 (ja
JP2010522137A (ja
Filing date
Publication date
Priority claimed from US11/638,282 external-priority patent/US7645750B2/en
Application filed filed Critical
Publication of JP2010522137A publication Critical patent/JP2010522137A/ja
Publication of JP2010522137A5 publication Critical patent/JP2010522137A5/ja
Application granted granted Critical
Publication of JP4643742B2 publication Critical patent/JP4643742B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (17)

  1. 閉経周辺期又は閉経期に関連するホルモン変化の1以上の症状を治療する又は予防するための医薬組成物であって、有効量のリスペリドン及び/又は9−ヒドロキシリスペリドンを含み、ここで、該症状は、のぼせ、動悸、おびただしい発汗、寝汗、めまい、頭痛、及び悪心からなる群から選ばれる、前記組成物。
  2. 前記症状が、のぼせ、及び/又は寝汗である、請求項1に記載の組成物。
  3. リスペリドンが投与される、請求項1に記載の組成物。
  4. リスペリドンの有効量が、成人患者に関して0.1〜50mg/日である、請求項3に記載の組成物。
  5. リスペリドンの有効量が、成人患者に関して0.1〜20mg/日である、請求項3に記載の組成物。
  6. リスペリドンの有効量が、成人患者に関して0.1〜6mg/日である、請求項3に記載の組成物。
  7. リスペリドンの有効量が、成人患者に関して0.1〜2mg/日である、請求項3に記載の組成物。
  8. 9−ヒロロキシリスペリドンが投与される、請求項1に記載の組成物。
  9. リスペリドンの有効量が、医薬として許容される製剤を用いて投与される、請求項3に記載の組成物。
  10. 前記医薬として許容される製剤は、経口製剤、注射製剤、吸入製剤、及び経皮パッチからなる群から選ばれる、請求項9に記載の組成物。
  11. 9−ヒドロキシリスペリドンの有効量が、成人患者に関して0.1〜50mg/日である、請求項8に記載の組成物。
  12. 9−ヒドロキシリスペリドンの有効量が、成人患者に関して0.1〜20mg/日である、請求項8に記載の組成物。
  13. 9−ヒドロキシリスペリドンの有効量が、成人患者に関して0.1〜6mg/日である、請求項8に記載の組成物。
  14. 9−ヒドロキシリスペリドンの有効量が、成人患者に関して0.1〜2mg/日である、請求項8に記載の組成物。
  15. 9−ヒドロキシリスペリドンの有効量が、医薬として許容される製剤を用いて投与される、請求項8に記載の組成物。
  16. 前記医薬として許容される製剤は、経口製剤、注射製剤、吸入製剤、及び経皮パッチからなる群から選ばれる、請求項15に記載の組成物。
  17. リスペリドンと9−ヒロロキシリスペリドンの混合物が投与される、請求項1に記載の組成物。
JP2009540891A 2006-12-13 2007-11-27 ホルモン変化の症状を治療する又は予防するための方法 Expired - Fee Related JP4643742B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/638,282 US7645750B2 (en) 2006-12-13 2006-12-13 Method of treating symptoms of hormonal variations
PCT/IB2007/004514 WO2008087491A2 (en) 2006-12-13 2007-11-27 Method for treating or preventing symptoms of hormonal variations

Publications (3)

Publication Number Publication Date
JP2010522137A JP2010522137A (ja) 2010-07-01
JP2010522137A5 true JP2010522137A5 (ja) 2010-08-26
JP4643742B2 JP4643742B2 (ja) 2011-03-02

Family

ID=39528142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009540891A Expired - Fee Related JP4643742B2 (ja) 2006-12-13 2007-11-27 ホルモン変化の症状を治療する又は予防するための方法

Country Status (11)

Country Link
US (3) US7645750B2 (ja)
EP (1) EP2101781B1 (ja)
JP (1) JP4643742B2 (ja)
KR (1) KR101435695B1 (ja)
CN (2) CN102697785B (ja)
AT (1) ATE506065T1 (ja)
CA (1) CA2671954C (ja)
DE (1) DE602007014102D1 (ja)
MY (1) MY162095A (ja)
TW (1) TWI330083B (ja)
WO (1) WO2008087491A2 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US8631151B2 (en) 2006-05-18 2014-01-14 Intel Corporation Techniques for guaranteeing bandwidth with aggregate traffic
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
CA2673481A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
US8420624B2 (en) * 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
NZ588037A (en) 2008-02-28 2012-08-31 Univ Virginia Patent Found Serotonin transporter gene SLC6A4 and treatment of alcoholism
US8461102B2 (en) 2010-03-02 2013-06-11 George E. Royster, JR. Methods and compositions for treating and preventing symptoms of hormonal variations
AU2011223807B2 (en) * 2010-03-02 2016-05-12 Fervent Pharmaceuticals, Llc Methods and compositions for treating or preventing symptoms of hormonal variations
US20130190299A1 (en) * 2010-06-30 2013-07-25 Victoria Link Ltd. Methods and compositions for treatment of multiple sclerosis
UA116615C2 (uk) * 2010-07-02 2018-04-25 Юніверсіті Оф Вірджінія Петент Фаундейшн Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
WO2012154174A1 (en) * 2011-05-10 2012-11-15 Liu Chui Yu Methods for treating insomnia
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
CN105744835A (zh) 2013-07-22 2016-07-06 俄亥俄州国家创新基金会 用于减少热潮红发生的方法
US11147856B2 (en) * 2015-04-07 2021-10-19 Meiji Co., Ltd. Hot flash-suppressing agent

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096254A (en) * 1976-05-10 1978-06-20 Richardson-Merrell Inc. Method of treating the symptoms of menopause and osteoporosis
FR2358892A1 (fr) * 1976-07-19 1978-02-17 Ile De France N(1'-allyl 2'-pyrrolidylmethyl)2,3-dimethoxy 5-sulfamoyl benzamide, ses derives
US5654011A (en) * 1996-07-30 1997-08-05 Energetics, Inc. Dietary supplements
EP1028690A2 (en) * 1997-10-20 2000-08-23 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
FR2779579B1 (fr) * 1998-06-09 2000-08-25 Thomson Csf Dispositif de commande optique pour l'emission et la reception d'un radar large bande
EP1202725B1 (en) * 1999-07-22 2007-04-11 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
US6613792B1 (en) * 1999-08-02 2003-09-02 Designed Nutritional Products, Inc. Treatment of premenstrual syndrome and menopause
ES2212737B1 (es) * 1999-08-13 2005-10-01 Vela Pharmaceuticals Inc. Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma.
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
PL364580A1 (en) * 2001-03-29 2004-12-13 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
WO2003037334A1 (en) * 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
CN1465348A (zh) 2002-07-05 2004-01-07 冯威健 复方消融合剂及其在用作制备治疗肿瘤药物上的应用
US20040127489A1 (en) * 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
US20040063721A1 (en) * 2002-08-15 2004-04-01 Wyeth Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction
JP2006514633A (ja) * 2002-11-26 2006-05-11 アレックザ ファーマシューティカルズ, インコーポレイテッド 吸入によって送達される抗精神病薬を用いた頭痛の治療
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
WO2005120523A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
TW200631584A (en) 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations

Similar Documents

Publication Publication Date Title
JP2010522137A5 (ja)
JP5781062B2 (ja) 不快な味を有する薬物を含有するフィルム製剤
JP2009525343A5 (ja)
HRP20121072T1 (hr) Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja
CN102892418A (zh) 含烟碱的药物组合物
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
JP2010525050A5 (ja)
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2010222367A5 (ja)
AR062167A1 (es) Sistema de administracion gastrorretentivo
JP2009517411A5 (ja)
JP2009518293A5 (ja)
CA2671954A1 (en) Methods for treating or preventing symptoms of hormonal variations
JP2017535613A5 (ja)
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2013516493A5 (ja)
WO2013123623A1 (zh) 一种口腔崩解片及其制备方法
Wang et al. Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease
JP2016505050A5 (ja)
TW200946142A (en) Tablet
JP2011500589A5 (ja)
JP2009534367A5 (ja)
WO2008120966A1 (es) Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor.